Loading...
SSKN logo

STRATA Skin Sciences, Inc.NasdaqCM:SSKN Stock Report

Market Cap US$8.1m
Share Price
US$1.27
n/a
1Y-52.9%
7D12.3%
Portfolio Value
View

STRATA Skin Sciences, Inc.

NasdaqCM:SSKN Stock Report

Market Cap: US$8.1m

STRATA Skin Sciences (SSKN) Stock Overview

A medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, China, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. More details

SSKN fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

SSKN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

STRATA Skin Sciences, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for STRATA Skin Sciences
Historical stock prices
Current Share PriceUS$1.37
52 Week HighUS$3.86
52 Week LowUS$1.18
Beta0.26
1 Month Change-8.67%
3 Month Change-33.50%
1 Year Change-52.92%
3 Year Change-82.88%
5 Year Change-90.62%
Change since IPO-99.96%

Recent News & Updates

Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt Sensibly?

Dec 19
Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt Sensibly?

Recent updates

Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt Sensibly?

Dec 19
Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt Sensibly?

STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Oct 18
STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Surges 36% Yet Its Low P/S Is No Reason For Excitement

There's No Escaping STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Muted Revenues Despite A 45% Share Price Rise

Sep 03
There's No Escaping STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Muted Revenues Despite A 45% Share Price Rise

Benign Growth For STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Underpins Its Share Price

Jul 03
Benign Growth For STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Underpins Its Share Price
User avatar

Improved XTRAC Utilization And Expanded International Partnerships Will Secure Success

Strategic removal of underperforming units and partnerships with clinics enhance device utilization and revenue potential.

Investors Don't See Light At End Of STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Tunnel And Push Stock Down 30%

Aug 18
Investors Don't See Light At End Of STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Tunnel And Push Stock Down 30%

Is STRATA Skin Sciences (NASDAQ:SSKN) Weighed On By Its Debt Load?

Aug 07
Is STRATA Skin Sciences (NASDAQ:SSKN) Weighed On By Its Debt Load?

STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Shares Lagging The Industry But So Is The Business

Jun 07
STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Shares Lagging The Industry But So Is The Business

Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt In A Risky Way?

Mar 19
Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt In A Risky Way?

STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Dec 31
STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Health Check: How Prudently Does STRATA Skin Sciences (NASDAQ:SSKN) Use Debt?

Nov 03
Health Check: How Prudently Does STRATA Skin Sciences (NASDAQ:SSKN) Use Debt?

We Think STRATA Skin Sciences (NASDAQ:SSKN) Has A Fair Chunk Of Debt

Jul 04
We Think STRATA Skin Sciences (NASDAQ:SSKN) Has A Fair Chunk Of Debt

STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Stock Rockets 26% But Many Are Still Ignoring The Company

Apr 18
STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Stock Rockets 26% But Many Are Still Ignoring The Company

Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt Sensibly?

Jan 14
Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt Sensibly?

STRATA Skin Sciences GAAP EPS of -$0.05 in-line, revenue of $9.1M beats by $0.96M

Aug 10

Strata Skin stock soars ~18% after hours on U.S. commercial launch of acne treatment

Jul 25

Shareholder Returns

SSKNUS Medical EquipmentUS Market
7D12.3%-0.5%-0.2%
1Y-52.9%5.0%17.1%

Return vs Industry: SSKN underperformed the US Medical Equipment industry which returned 5% over the past year.

Return vs Market: SSKN underperformed the US Market which returned 17.1% over the past year.

Price Volatility

Is SSKN's price volatile compared to industry and market?
SSKN volatility
SSKN Average Weekly Movement17.4%
Medical Equipment Industry Average Movement8.8%
Market Average Movement6.4%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market2.9%

Stable Share Price: SSKN's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: SSKN's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1989106Dolev Rafaeliwww.strataskinsciences.com

STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, China, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. It operates through two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. The company offers XTRAC excimer laser and VTRAC lamp systems, which are used in the treatment of psoriasis, vitiligo, and other skin conditions; and TheraClear acne therapy system for the treatment of mild to moderate inflammatory, comedonal, and pustular acne.

STRATA Skin Sciences, Inc. Fundamentals Summary

How do STRATA Skin Sciences's earnings and revenue compare to its market cap?
SSKN fundamental statistics
Market capUS$8.07m
Earnings (TTM)-US$10.87m
Revenue (TTM)US$30.98m
0.3x
P/S Ratio
-0.7x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SSKN income statement (TTM)
RevenueUS$30.98m
Cost of RevenueUS$13.09m
Gross ProfitUS$17.89m
Other ExpensesUS$28.76m
Earnings-US$10.87m

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-1.85
Gross Margin57.74%
Net Profit Margin-35.10%
Debt/Equity Ratio1,165.1%

How did SSKN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/30 20:54
End of Day Share Price 2025/12/29 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

STRATA Skin Sciences, Inc. is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullCG Capital
Jeffrey CohenLadenburg Thalmann & Company
John SullivanLeerink Partners LLC